AB 19
Alternative Names: AB-19Latest Information Update: 20 Aug 2024
Price :
$50 *
At a glance
- Originator AUTOTAC Bio
- Class
- Mechanism of Action Apoptosis stimulants; Tau protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Progressive supranuclear palsy
Most Recent Events
- 02 Aug 2024 AUTOTAC Bio plans a phase I trial for Progressive supranuclear palsy in between 2024 to 2025 (Unspecified route) (AUTOTAC Bio pipeline, August 2024)
- 02 Aug 2024 Preclinical trials in Progressive supranuclear palsy in South Korea (unspecified route) (AUTOTAC Bio Pipeline, August 2024)
- 02 Aug 2024 AUTOTAC Bio plans a phase II trial for Progressive supranuclear palsy in between 2025 to 2026 (Unspecified route) (AUTOTAC Bio pipeline, August 2024)